http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11254696-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4cd9a2ae528abb61034e08fa7c2d918 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65583 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6512 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-48 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6512 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6558 |
filingDate | 2018-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2022-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e0ad813d41711fbe6bbb6be995a8837 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da3044eac224813411b3ef868c3e1c9f |
publicationDate | 2022-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-11254696-B2 |
titleOfInvention | Dianilinopyrimidine compound for inhibiting kinase activity |
abstract | Disclosed are a dianilino pyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotopic derivatives thereof, a pharmaceutical composition containing these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and may be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia. |
priorityDate | 2017-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1028.